Loading…
← CockpitCompetitor Analysis › 007390.KS NATURECELL Co., Ltd.Open in the cockpit ↗

NATURECELL Co., Ltd.007390.KSCompetitor analysis, valuation and peers

South Korea · KRW·Consumer Staples›Beverages: Non-Alcoholic

Korean biotech developing autologous stem-cell therapies, including a knee-osteoarthritis treatment, made from patients' own fat tissue.

Momentum leader 87
Mkt cap
$1.03B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$3.85M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-20.8 pp
WACC 8.2%
Hurdle
n/a
no reverse DCF
Close · KRW₩21,450
1D-1.6%
1W-3.6%
1M-7.5%
3M-8.3%
6M+17.5%
YTD-1.6%
1Y-13.2%
ATR %6.0%
52w lowhigh42.0% off high

What NATURECELL does

Korean biotech developing autologous stem-cell therapies, including a knee-osteoarthritis treatment, made from patients' own fat tissue.

Products and services

  • JOINTSTEM (knee osteoarthritis stem-cell therapy)
  • Stem-cell banking services

Customers

  • Orthopedic clinics/hospitals (licensees)

Where it sits in the supply chain

  • Biotechnology
  • Autologous stem-cell therapeutics
  • Cell-therapy clinical development

What could go right

  • Regulatory approval in new markets

What could go wrong

  • Clinical/regulatory setback risk
  • Past governance/promotion controversies

Moat: narrow (IP / patents, regulatory licence). Patented autologous stem-cell process, though facing efficacy/regulatory skepticism.

Headquarters: Seoul, South Korea · Founded: 2002 · Employees: 83

Named competitors

NATURECELL at a glance

Size NATURECELL (007390.KS) is a South Korea Consumer Staples company (Beverages: Non-Alcoholic) with a market value of $1.03B, the 234th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩21,450 on 18 Nov 2026.

Performance Over six months the shares gained 17.5%, against -2.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 14.5% over the last twelve months (peer median +2.7%); the operating margin is -53.5% (peer median 8.2%).

Valuation It trades at 72.8× enterprise value to sales against a peer median of 1.5× (most expensive of 21).

Capital Return on invested capital runs 20.8 points below its cost of capital (8.2% WACC).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026007390.KS 119Peer median 97
Six months, rebased to 100: NATURECELL against the median of its 20 peers (local-currency closes).

NATURECELL financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩18.9B₩20.7B₩32.3B₩19.4B₩21.3B
Revenue growth—-36%+67%-9%—
Gross profit₩8.22B₩8.15B₩15.5B₩7.05B₩8.41B
EBITDA-₩8.05B-₩1.82B₩2.48B-₩8.82B-₩8.10B
Net income-₩10.7B-₩2.84B₩1.23B-₩11.7B-₩10.3B
Free cash flow-₩31.4B-₩16.4B-₩1.59B-₩8.25B-₩18.7B
Capital expenditure₩17.1B₩16.6B₩3.12B₩6.12B₩3.80B
Total debt₩33.0B₩7.80B₩1.78B₩2.31B₩25.5B

Quarterly statements and history in the cockpit →

NATURECELL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-10%0%+10%+20%-10%0%LAS-A000019BAGPRN005300FEVR05062590000716NICL605337258824602585600962123411152573FIZZY03007390.KS6-month return →1-month return →
Up and to the right = strong over both horizons. NATURECELL is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×20×40×60×LAS-A000019PRN000716246025856009621115007390.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NATURECELL is the large dot.

NATURECELL competitors and peer comparison

Head to head with its named competitors (007390.KS vs 085660.KS vs MSB.AX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
NATURECELL 007390.KS$1.03B+17%-15%-54%72.8×n/a
CHA Biotech 085660.KS$523M-52%+4%-7%1.4×n/a
Mesoblast MSB.AX$1.49B-17%+556%-43%12.8×n/a

How NATURECELL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NATURECELL against its 20 peers (data as of 18 Nov 2026)
Measure007390.KSPeer medianRank in peer set
1-month return-7.5%0.0%4th lowest of 21
6-month return+17.5%-2.0%4th highest of 21
Distance from 52-week high-42.0%-19.0%3rd lowest of 21
Revenue growth (TTM)-14.5%+2.7%2nd lowest of 21
Operating margin-53.5%8.2%lowest of 20
EV / Sales72.8×1.5×most expensive of 21
ROIC minus cost of capital-20.8 pp+0.5 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
NATURECELL 007390.KSSouth Korea$1.03B+17%-15%-54%72.8×n/an/a
Lassonde Industries LAS-A.TOCanada$1.05B+9%-1%9%0.7×-12.9%+8.2%
Shenzhen Cereals 000019.SZChina$979M-17%+1%6%1.5×3.9%-14.3%
A.G. BARR p.l.c BAG.LUnited Kingdom$885M-2%+7%15%1.6×n/an/a
Princes PRN.LUnited Kingdom$1.28B+28%+30%4%0.4×-5.0%+9.3%
LotteChilsung 005300.KSSouth Korea$771M-13%0%4%0.6×0.1%+12.0%
Fevertree Drinks FEVR.LUnited Kingdom$1.39B+25%+2%9%2.9×29.2%+5.2%
China Foods 0506.HKHong Kong$1.42B+14%+4%8%0.4×-16.8%+4.3%
DyDo 2590.TJapan$612M+16%+3%4%0.4×n/an/a
Nanfang Black Sesame 000716.SZChina$554M-7%+14%3%1.8×11.0%-10.1%
Nichols NICL.LUnited Kingdom$543M+19%+3%18%1.9×1.0%+8.1%
Zhe Jiang Li Zi Yuan Food 605337.SSChina$501M-16%-4%12%2.9×n/an/a
Premium Water 2588.TJapan$493M0%+5%16%1.5×-10.6%+7.4%
China Resources Beverage (Holdings) 2460.HKHong Kong$2.28B-9%-19%6%1.0×n/an/a
Lifedrink 2585.TJapan$430M-2%+23%10%1.6×n/an/a
SDIC Zhonglu Fruit Juice 600962.SSChina$2.53B-16%+100%n/a3.7×n/an/a
Hey-Song 1234.TWTaiwan$384M-7%-3%5%1.5×12.1%+0.7%
5100 Xizang Glacier 1115.HKHong Kong$364M+7%+67%21%8.0×n/an/a
Hokkaido Coca-Cola Bottling 2573.TJapan$336M-4%+3%3%0.8×8.5%+2.8%
National Beverage FIZZUnited States$3.50B+6%-2%18%2.9×3.8%+1.9%
Yeo Hiap Seng Y03.SISingapore$259M-12%-3%-7%0.5×n/an/a

Questions

Who are NATURECELL's main competitors?
Named competitors: CHA Biotech (085660.KS), Mesoblast (MSB.AX). The cockpit's measured peer set (industry) also includes Lassonde Industries (LAS-A.TO), Shenzhen Cereals (000019.SZ), A.G. BARR p.l.c (BAG.L), Princes (PRN.L), LotteChilsung (005300.KS), Fevertree Drinks (FEVR.L).
Is NATURECELL expensive compared with its peers?
On ev / sales it trades at 72.8× against a peer median of 1.5×, most expensive of 21 in its peer set.
How has NATURECELL stock performed?
Over six months to 18 Nov 2026 the shares returned +17.5% against -2.0% for the median peer; over one year -13.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.